Today, May 30, 2018, Trump signed S. 204, the “Right to Try Act,” giving the terminally ill more access to treatments outside of clinical trials. The Right to Try is intended to help patients, particularly cancer patients, who are not enrolled in clinical trial opportunities to try medications that are not yet FDA approved.
The act also intends to protect physicians, pharmacies, and drug companies from legal repercussions resulting from unsuccessful patient experiences with experimental drugs.
Previously, the Right to Try was approved on a state level in 40 states.